PMID- 19881334
OWN - NLM
STAT- MEDLINE
DCOM- 20100914
LR  - 20141120
IS  - 1473-5849 (Electronic)
IS  - 0955-8810 (Linking)
VI  - 20
IP  - 8
DP  - 2009 Dec
TI  - Effect of D1-like and D2-like receptor antagonists on methamphetamine and 
      3,4-methylenedioxymethamphetamine self-administration in rats.
PG  - 688-94
LID - 10.1097/FBP.0b013e328333a28d [doi]
AB  - It has been suggested that activation of dopamine D1-like and D2-like receptors 
      contribute equally to the maintenance of drug self-administration. This study 
      compared the contribution of these receptor subtypes to 
      3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine (MA) 
      self-administration. Effects of pretreatment with the D2-like receptor 
      antagonist, eticlopride (0.0, 0.0125, 0.025 or 0.05 mg/kg, intraperitoneal), on 
      responding maintained by several doses of MDMA (0.5, 1.0 and 2.0 mg/kg/infusion) 
      and MA (0.05, 0.1 and 0.2 mg/kg/infusion) were determined. As we have published 
      data showing the effects of the D1-like receptor antagonist, SCH23390 (0.0, 0.01 
      or 0.02 mg/kg, subcutaneous), on MDMA self-administration, effects of this dose 
      range on the MA dose-response curve were determined. In our previous study, 0.02 
      mg/kg SCH23390 produced a rightward shift in the MDMA dose response curve, 
      whereas in the present results, this dose decreased responding maintained by most 
      doses of MA. Eticlopride increased the responding maintained by most doses of 
      MDMA but failed to alter MA self-administration. The present results suggest that 
      both D1-like and D2-like receptors contribute to the maintenance of MDMA 
      self-administration, whereas MA self-administration was more sensitive to D1-like 
      receptor blockade.
FAU - Brennan, Katharine A
AU  - Brennan KA
AD  - Institute of Environmental Science and Research Ltd., Porirua, New Zealand. 
      katie.brennan@damascene.co.nz
FAU - Carati, Caleb
AU  - Carati C
FAU - Lea, Rod A
AU  - Lea RA
FAU - Fitzmaurice, Paul S
AU  - Fitzmaurice PS
FAU - Schenk, Susan
AU  - Schenk S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Behav Pharmacol
JT  - Behavioural pharmacology
JID - 9013016
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Benzazepines)
RN  - 0 (Dopamine D2 Receptor Antagonists)
RN  - 0 (Receptors, Dopamine D1)
RN  - 0 (SCH 23390)
RN  - 0 (Salicylamides)
RN  - 44RAL3456C (Methamphetamine)
RN  - I5Y540LHVR (Cocaine)
RN  - J8M468HBH4 (eticlopride)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Antipsychotic Agents/administration & dosage/pharmacology
MH  - Benzazepines/administration & dosage/*pharmacology
MH  - Central Nervous System/drug effects
MH  - Cocaine/administration & dosage/metabolism
MH  - *Dopamine D2 Receptor Antagonists
MH  - Dose-Response Relationship, Drug
MH  - Male
MH  - Methamphetamine/*administration & dosage/metabolism
MH  - Motor Activity/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Dopamine D1/*antagonists & inhibitors
MH  - Salicylamides/administration & dosage/*pharmacology
MH  - Self Administration
EDAT- 2009/11/03 06:00
MHDA- 2010/09/15 06:00
CRDT- 2009/11/03 06:00
PHST- 2009/11/03 06:00 [entrez]
PHST- 2009/11/03 06:00 [pubmed]
PHST- 2010/09/15 06:00 [medline]
AID - 10.1097/FBP.0b013e328333a28d [doi]
PST - ppublish
SO  - Behav Pharmacol. 2009 Dec;20(8):688-94. doi: 10.1097/FBP.0b013e328333a28d.